FORGE Life Science Head
of Biology, Eain Murphy, presents, “Targeting Host-cell Metabolism to Address
Respiratory Viruses”, at the 6th International Society for Influenza
and Other Respiratory Virus Diseases (ISIRV) Antiviral Group Conference –
Advanced Respiratory Virus Therapeutics, Rockville, MD.
FORGE Life Science is
awarded its first Department of Defense STTR contract (W911QY18P0300) from the
Joint Project Manager Medical Countermeasure Systems. Proposal titled, “Host-Targeted
Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum Medical
Countermeasure Against Marburg Virus”.
FORGE Life Science CEO, Lillian Chiang, presents at the National
Institutes of Health CMV Workshop, Cytomegalovirus Infection: Advancing
Strategies for Prevention and Treatment.
The European Patent Office grants patent EP 2670404 B1, allowing claims
directed to antiviral treatments with inhibitors of two or more sirtuins. This
I.P. is exclusively licensed by FORGE from Princeton University. Read more
May 29, 2019:
NewsFORGE Life Science is now Evrys Bio. Read more
April 17, 2019:
NewsFORGE Life Science secures $1.0 M in bridge financing from its strategic investors.
November 13, 2018:
NewsFORGE Life Science Head of Biology, Eain Murphy, presents, “Targeting Host-cell Metabolism to Address Respiratory Viruses”, at the 6th International Society for Influenza and Other Respiratory Virus Diseases (ISIRV) Antiviral Group Conference – Advanced Respiratory Virus Therapeutics, Rockville, MD.
September 25, 2018:
NewsFORGE Life Science is awarded its first Department of Defense STTR contract (W911QY18P0300) from the Joint Project Manager Medical Countermeasure Systems. Proposal titled, “Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum Medical Countermeasure Against Marburg Virus”.
September 4, 2018:
NewsFORGE Life Science CEO, Lillian Chiang, presents at the National Institutes of Health CMV Workshop, Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment.
August 29, 2018:
NewsThe European Patent Office grants patent EP 2670404 B1, allowing claims directed to antiviral treatments with inhibitors of two or more sirtuins. This I.P. is exclusively licensed by FORGE from Princeton University. Read more